Aerovate slashes workforce after failed Phase IIb trial

2024-07-02

Preview

来源: Pharmaceutical Technology

Pulmonary hypertension is high blood pressure in the blood vessels that supply the lungs. Credit: Andrew Angelov via Shutterstock.

Aerovate Therapeutics is slashing its workforce by 78%, two weeks after the company announced a Phase IIb trial failure of its pulmonary arterial hypertension (PAH) drug AV-101.

The Massachusetts-based biotech announced the downsizing in an SEC filing where Aerovate said it expects to incur costs of about $5.6m related to the layoffs. These costs are expected to be incurred in the third and fourth quarters of 2024. The company also added that it expects all of its workforce to be cut in the coming months.

On 17 June, Aerovate shut down its Phase II/III IMPAHCT trial (NCT05036135) after the Phase IIb section did not meet its primary endpoint for improvement in PAH compared to placebo for any of the studied doses. AV-101—an inhaled version of the drug imatinib—also failed to show meaningful improvements in the secondary endpoint of change in six minute walk distance. The Phase III and long-term extension arms (NCT05557942) were consequently stopped, with Aerovate’s stock price plummeting over 90% following the announcement.

PAH is a condition characterised by high blood pressure, leading to strain on the heart and reduced oxygenation. Competition in the PAH market has increased over the past year, with MSD’s Winrevair (sotatercept-csrk) and Johnson & Johnson’s Opsynvi—a combination of drugs Adcirca (tadalafil) and Opsumit (macitentan)—both gaining US Food and Drug Administration (FDA) approval in March 2024.

Imatinib is a small molecule tyrosine kinase inhibitor (TKI) that blocks signalling by binding to the ATP-binding pocket necessary for receptor activation. Marketed by Novartis as Gleevec, imatinib is available as a generic cancer treatment.

See Also:Biogen completes $1.15bn HI-Bio acquisition to expand immunology presence

Preview

来源: Pharmaceutical Technology

EMA approves Sanofi’s Dupixent for COPD treatment in adults

Preview

来源: Pharmaceutical Technology

Oral imatinib has been shown to be effective, but poorly tolerated in patients with PAH. Therefore, AV-101, a dry powder inhaled formulation of imatinib, was developed to avoid systemic exposure by delivering the therapy directly to the lungs.

Aerovate launched back in 2020 with $72.6m in Series A funding round led by Sofinnova Investments. The money was meant to advance trials of AV-101, which was its lead and only clinical candidate.

According to a report on GlobalData’s Pharma Intelligence Center, PAH market sales will be worth $7.4bn in the seven major markets (US, UK, France, Germany, Italy, Spain, and Japan) in 2029.

GlobalData is the parent company of Pharmaceutical Technology.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构